Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study - Wikidata - wikimedia - TriplyDB

Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study

Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study

http://www.wikidata.org/entity/Q34446365

about

Insights on common vaccinations in HIV-infection: efficacy and safety Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus.Increased risk of herpes zoster in children with cancer: A nationwide population-based cohort study.Varicella zoster virus infection.Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II.Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future?The herpes zoster subunit vaccine.Vaccines for the prevention against the threat of MERS-CoV.Surveillance of Vaccination Coverage among Adult Populations - United States, 2015.Herpes zoster and the search for an effective vaccine.A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus.Varicella Zoster Virus and Giant Cell Arteritis.Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.Vaccines for the elderly: current use and future challenges.Herpes Zoster in the Older Adult.Varicella and herpes zoster vaccine development: lessons learned.The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes.The adjuvant system AS01 up-regulates neutrophil CD14 expression and neutrophil-associated antigen transport in the local lymphatic network.A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile Herpes Zoster DNA Vaccines with IL-7 and IL-33 Molecular Adjuvants Elicit Protective T Cell Immunity

P2860

Q26770665-235965D6-824C-42F9-A0EC-68BBE6274D5C Q33724403-8C820228-D8E0-489B-AAE2-A7608CDADE41 Q36024466-3B257462-567E-4CBC-9CB4-F5BB3DF1A230 Q37605555-5260012C-375F-4D42-BDF0-11F3DB2D3F38 Q37738789-B3895F5A-2A61-4760-BDE6-36AACB37DD9A Q38638518-548E782B-0600-4D66-AD91-5B8A42B7C24A Q38667215-CD70CBE8-65A6-4DFC-A636-E9ABE2379517 Q38728931-1516E23C-453A-4DB7-BE00-9AA7F1DF7732 Q38778044-3DCFB2A8-3EDD-444B-B239-A7D961148C7E Q38804622-1FA494BB-B31A-44B8-973C-27819562514B Q38831062-C5A9C96C-BF06-4F98-AB46-CACA49D1FD38 Q40234780-1FC50C72-C7FC-4FFF-BE84-FAB6719A8BE2 Q42765034-4F27CD38-F3F4-4388-A59B-5A4F759EC52E Q46892547-20B7F31A-27E4-42C5-B521-528A4719F535 Q47547388-6663F566-9CE8-4031-9B73-4D02C9F2EBFD Q47597541-2A270416-CA7C-4E7F-BBB5-38A11BB7B444 Q47607699-FE65BB37-AEBE-466B-BA6D-AB5363BB440F Q48101757-FE870225-AA4E-46AB-B424-ABE7619A16A5 Q48197943-34E3406D-D5D1-47F4-B714-AF5C26D6FF48 Q56888201-7BA80A1D-6589-43A0-A2BA-C949CAA22C0A Q58584452-5A01D27C-A506-4C45-9948-E150251B885A

P2860

Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study

http://www.wikidata.org/entity/Q34446365

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Safety and immunogenicity of a ...... ized, placebo-controlled study

@ast

Safety and immunogenicity of a ...... ized, placebo-controlled study

@en

Safety and immunogenicity of a ...... ized, placebo-controlled study

@nl

type

label

Safety and immunogenicity of a ...... ized, placebo-controlled study

@ast

Safety and immunogenicity of a ...... ized, placebo-controlled study

@en

Safety and immunogenicity of a ...... ized, placebo-controlled study

@nl

prefLabel

Safety and immunogenicity of a ...... ized, placebo-controlled study

@ast

Safety and immunogenicity of a ...... ized, placebo-controlled study

@en

Safety and immunogenicity of a ...... ized, placebo-controlled study

@nl

P1433

Q34446365-D89921B3-8B6C-4D15-AE79-FE6DCEB458F7

P1476

Q34446365-55650250-0158-45BD-91FC-BB6E5F54031E

P2093

Q34446365-28C9B375-2A7B-4FA3-8F51-6C6D9904389A

Q34446365-3442CBFD-871F-49D0-A868-EC55701CD794

Q34446365-82830A95-C2D4-4329-B50D-A71BD7FC53EB

Q34446365-9AB1A534-EB3B-45B3-8D21-E38A2ACD1866

Q34446365-B3AC21C2-D9C3-472E-A473-BF12149B6199

Q34446365-B59856BF-6370-4D66-8B23-B9C3E640AB40

Q34446365-C2B0BF23-76BE-458B-897E-ACC754C5FC2B

Q34446365-D375F6B9-D51E-48B1-A0CC-7F2DC80C47FA

Q34446365-DFB667B9-ED91-443C-BBE0-4848C72915A7

Q34446365-FEDDB7B4-6F95-4E51-86CE-C34AC75DD400

P2860

Q34446365-06EE4831-35E1-49E3-BF97-9AEF07D98956

Q34446365-193E7FC9-3203-4FFF-8065-1CBEE6304958

Q34446365-1DDC012C-3A3C-49C4-AE99-E81E659C66D3

Q34446365-21407269-DD20-4198-B593-EDA1050B2609

Q34446365-3186E88F-84AE-42C7-A783-9F05EADCCF8C

Q34446365-33FA4D1A-2EF9-4EB4-BC54-571F044D7D7B

Q34446365-34B68229-80EF-4016-AC1F-16445E413887

Q34446365-56462D77-0B2D-4AAE-A9B4-73503C257154

Q34446365-59A3350B-69D0-4980-96F1-DD5F5475AEF3

Q34446365-59F3D633-9B07-432D-8B14-2F0BD184645C

P304

Q34446365-D294705B-3F62-4E2F-82E9-5D87A751C0FF

P31

Q34446365-DC0B9DB3-9F5B-4997-AA5E-7080A9982506

P356

Q34446365-0EFF7C99-17E4-4AC6-99EF-A0706A49EDC6

P407

Q34446365-B98C964B-BB17-49F7-8FBD-554D3FBAE08C

P433

Q34446365-7ADA89F7-44CF-4A02-B360-A3311D90AB04

P478

Q34446365-525C6AB7-6337-4C59-B70E-31F96C02E491

P50

Q34446365-B58CF877-41BA-40C4-87E8-38D5EE439A0A

P577

Q34446365-3A169298-7055-4B8A-8C59-E9623DDF5A0F

P5875

Q34446365-12434CC6-1A00-4133-99A3-94B037948AEF

P698

Q34446365-C4591695-B499-4B31-AA88-9B6810B5580D

P921

Q34446365-AE8DB0A3-E93E-489A-99D1-ADB62BAC850D

P932

Q34446365-A9576421-057B-42D2-8186-570CBBAB9063

P356

P1433

The Journal of Infectious Diseases

P1476

Safety and immunogenicity of a ...... ized, placebo-controlled study

@en

P2093

Dirk Schürmann

http://www.w3.org/2001/XMLSchema#string

Elchonon M Berkowitz

http://www.w3.org/2001/XMLSchema#string

Graeme Moyle

http://www.w3.org/2001/XMLSchema#string

Hans-Jürgen Stellbrink

http://www.w3.org/2001/XMLSchema#string

Lidia Oostvogels

http://www.w3.org/2001/XMLSchema#string

Matthias Stoll

http://www.w3.org/2001/XMLSchema#string

Mohamed El Idrissi

http://www.w3.org/2001/XMLSchema#string

Stephen Kegg

http://www.w3.org/2001/XMLSchema#string

Thomas C Heineman

http://www.w3.org/2001/XMLSchema#string

Zoster-015 HZ/su Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction

Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008

Herpes zoster and the stage and prognosis of HIV-1 infection

Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Herpes zoster among persons living with HIV in the current antiretroviral therapy era.

Herpes zoster and human immunodeficiency virus infection.

A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.

Recombinant subunit vaccines: potentials and constraints.

Zoster vaccine: current status and future prospects.

Pathogenic mechanisms of HIV disease.

P304

1279-1287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIU606

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

211

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Jürgen Stellbrink

P577

2014-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267933239

http://www.w3.org/2001/XMLSchema#string

P698

25371534

http://www.w3.org/2001/XMLSchema#string

P921

P932

4371767

http://www.w3.org/2001/XMLSchema#string